Key Highlights

● SelectQuote Inc. shares ticked up modestly to roughly $0.73 to $0.75 in mid-August 2026.

● An NYSE minimum-price compliance deadline looms this fall, adding listing pressure to the stock.

● The company continues managing fallout from a Department of Justice civil Fraud intervention filed in May 2025.

● SelectQuote, the Overland Park, Kansas-based Medicare Advantage distributor and owner of the SelectRx home pharmacy, reports fiscal fourth-quarter and full-year 2026 results on August 25.

SelectQuote Inc. (NYSE: SLQT), the Overland Park, Kansas-based Medicare Advantage distributor and owner of the SelectRx home pharmacy, saw its shares tick up modestly this week to roughly $0.73–$0.75, according to market data checked in mid-August 2026. No single company-specific announcement could be independently verified as explaining the move; the stock remains near the bottom of its 52-week range of $0.56 to $2.77. The bigger story is structural: SelectQuote is racing against an NYSE minimum-price compliance deadline this fall while awaiting fiscal fourth-quarter and full-year 2026 results, scheduled for release before the market open on August 25, and continuing to manage fallout from a Department of Justice civil fraud intervention filed in May 2025.

Latest Development

SelectQuote confirmed in a company release that it will report fiscal Q4 and full-year 2026 Earnings on August 25, 2026, with CEO Tim Danker and CFO Ryan Clement hosting a call at 8:30 a.m. ET. That announcement, made roughly three days before this writing, appears to be the most recent company-specific news event. It follows a March 25, 2026 disclosure that SelectQuote received a New York Stock Exchange continued-listing notice because its common stock's average closing price fell below $1.00 over a consecutive 30-trading-day period. Under NYSE rules, the company has a six-month cure period, meaning roughly through late September 2026, to close at $1.00 or higher on the last trading day of any month with a trailing 30-day average also at or above $1.00. As of mid-August, shares were still trading in the $0.70s, below that threshold. The company said at the time it would "closely monitor its stock price" and pointed to a new $415 million Credit Facility and projected fiscal 2026 Operating Cash Flow of $25 million to $35 million as evidence of financial capacity to address the issue, which could include a Reverse Stock Split if the price does not organically recover.

What the Numbers Show

The last verified quarterly print is fiscal Q3 2026 (quarter ended March 31, 2026), reported May 5, 2026. Total Revenue was $430.9 million, up from $408.2 million a year earlier. Net Income rose to $40.2 million from $26.0 million, and adjusted EBITDA climbed 18% year-over-year to $44.6 million. Reported EPS of $0.11 came in well ahead of the roughly $0.02 analyst consensus, and the earnings beat reportedly drove a sharp single-day stock rally at the time.

By segment, Senior (Medicare Advantage distribution) generated $182.9 million in revenue, up 8%, with adjusted EBITDA up 28% to $58.6 million, a roughly 32% margin. The company sold 175,557 Medicare Advantage approved policies and 196,709 total approved policies in the quarter, and its trailing-12-month revenue-to-customer-acquisition-cost multiple improved to 6.7x, up from 4.2x two years earlier, alongside a 14% reduction in Marketing expense per policy. Healthcare Services (SelectRx) revenue was $199.4 million, up 5%, with SelectRx membership at 116,616, up 11% year-over-year, and daily prescription Volume of roughly 33,000, up from about 20,000 a year prior; segment adjusted EBITDA was $5.3 million. Life segment revenue was $47.9 million with $6.1 million of adjusted EBITDA. For the nine months ended March 31, 2026, revenue totaled $1.30 billion, net income was $79.0 million, and adjusted EBITDA was $97.2 million.

On the Balance Sheet as of March 31, 2026, SelectQuote held $35.2 million in cash and equivalents, $234.3 million in accounts receivable, and $959.5 million in commissions receivable (current and long-term combined), a large asset tied to future Medicare Advantage renewal commissions. Total Debt was $375.8 million. Management reaffirmed full fiscal-year 2026 guidance of $1.61 billion to $1.71 billion in revenue and $90 million to $100 million in adjusted EBITDA, alongside the $25 million to $35 million operating cash flow target tied to the new $415 million credit facility.

Why Investors Are Paying Attention

SelectQuote sits at the intersection of two competing narratives. Operationally, the Senior segment has shown genuine Margin recovery after years of Medicare Advantage industry turbulence, and SelectRx has scaled toward a targeted $40–$50 million adjusted EBITDA run rate that management has cited as a milestone. Yet the Equity trades like a distressed micro-cap, with a market Capitalization of roughly $130 million and a share price that has fallen from a 52-week high near $2.77 to under $1. That disconnect, improving fundamentals against a share price under NYSE minimum-listing pressure, is the central tension investors are weighing heading into the August 25 print.

Bull Case

Bulls point to accelerating adjusted EBITDA growth (up 18% in the most recent quarter), expanding Senior segment margins, a much-improved customer Acquisition cost multiple, double-digit SelectRx membership growth, and a new multiyear PBM agreement for SelectRx (announced in January 2026) that management says supports financial consistency. The company also launched "SelectQuote Local" in March 2026 as an additional distribution channel. Reaffirmed guidance and a new $415 million credit facility suggest management believes Liquidity is adequate to fund growth and legal costs without near-term distress.

Bear Case

Bears note the stock's proximity to NYSE delisting territory, which could force a reverse split or trigger forced selling by index or institutional holders with minimum-price mandates. The company also faces a DOJ civil fraud intervention (filed May 1, 2025, in a False Claims Act Whistleblower case) alleging SelectQuote received improper payments tied to Medicare Advantage kickback arrangements from 2016 through at least 2021, plus a related securities class action, Pahlkotter v. SelectQuote et al., covering a September 2020–May 2025 class period. That litigation carries uncertain financial and reputational exposure. Total debt of $375.8 million against thin cash reserves of $35.2 million also leaves limited balance-sheet cushion if litigation costs or Medicare policy changes pressure cash flow.

What Could Move the Stock Next?

The most immediate catalysts are the fiscal Q4/full-year 2026 earnings release and call on August 25, 2026, and any update on progress toward the NYSE $1.00 minimum-price cure deadline in late September. Developments in the DOJ litigation or securities class action, changes to Medicare Advantage commission or marketing rules from CMS, and any announcement of a reverse stock split would also likely move shares materially given the stock's low absolute price and small float value.

A Modest Tick Higher, Two Clouds Still Overhead

SelectQuote's underlying Business has shown clearer operating improvement in recent quarters, rising adjusted EBITDA, healthier Senior segment margins, and SelectRx membership growth, than its depressed share price might suggest. But the stock's slide below $1 and the resulting NYSE compliance clock, layered on top of unresolved DOJ and securities litigation tied to historical Medicare Advantage marketing practices, mean the market is pricing meaningful uncertainty independent of quarterly execution. The August 25 fiscal fourth-quarter report will be the next concrete data point testing whether operational momentum can outrun these structural and legal overhangs.